Transaction · 0001159036-26-000117

Appelhans Dannielle

Appelhans Dannielle, DIR, reported a transaction classified as grant at HALOZYME THERAPEUTICS, INC. involving 1778.000000 shares for an estimated $0.00. Reported holdings after the transaction were 1778.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ADIR
HALOHALOZYME THERAPEUTICS, INC.
Filing timeSep 02
Trade dateSep 01, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$109.66
Pre-filing
1mo ago -24.7%1w ago -0.6%1d ago -2.9%
Returns since
7d +0.0%30d +0.0%90d +0.0%180d +0.0%1y +0.0%

HALO price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
HALO since 2026-09-02Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001159036-26-000117
Option to Purchase Common Stock
Transaction date
Sep 01, 2026
Filed Sep 02, 2026, 08:59 PM · 1d delay
Shares
1.77k sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
1.77k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Derivative Transaction Direct Ownership Large Holdings Increase
-6score
Filing-only score

-6

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the

  2. date of the Issuer's 2027 annual meeting of stockholders.

  3. F2

    Represents stock options granted under the Issuer's director compensation program. This grant will vest in full on the date of the Issuer's 2027 annual meeting of stockholders.

Original filing · 0001159036-26-000117
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

HALO